Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People
Sponsor: Novo Nordisk A/S
Summary
The study is testing a new study medicine, which is being tested as a potential medicine to treat cardiometabolic diseases. The aim of this study is to see if the study medicine is safe, how it works in participants body, and what the body does to the study medicine. Participants will either get NNC6022-0001 (the new study medicine) or placebo (a "dummy medicine" without the active ingredient). Which treatment participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors. The study will last for about 10 months in total.
Official title: A First Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Target Engagement of Single Doses of NNC6022-0001 in Healthy Adults.
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2024-03-28
Completion Date
2025-02-17
Last Updated
2026-06-30
Healthy Volunteers
Yes
Interventions
NNC6022-0001
Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts.
Placebo (NNC6022-0001)
Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts
Locations (1)
ICON - location Groningen
Groningen, Netherlands